MSD getting closer to USD 40bn acquisition of Seagen, media reports

The two companies are discussing a price of over USD 200 per share and a final agreement by July 28.
Photo: MSD / PR
Photo: MSD / PR
by marketwire, translated by catherine brett

US-based pharmaceutical giant MSD is in advanced negotiations concerning the acquisition of Seagen, a biotech firm focusing on oncology, for around USD 40bn, the Wall Street Journal reports after speaking to people close to the matter.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading